Adverse effect of dopamine agonist therapy in a patient with motor-intentional neglect

Arch Phys Med Rehabil. 1999 May;80(5):600-3. doi: 10.1016/s0003-9993(99)90205-8.

Abstract

Studies in animals and humans report dopamine agonists can improve neglect. Because dopamine deficit reduces intention to act, it has been suspected the dopamine agonist bromocriptine would improve deficient hemispatial intention. Thus, the effect of bromocriptine on line bisection was examined in a patient with neglect and failure of the action-intention system. The 58-year-old patient had left-sided neglect from a right cerebral infarction involving both cortical and subcortical (striatal) structures. It was determined that neglect on a line bisection task was attributable to a motor-intentional bias by testing under congruous and incongruous video monitoring. Testing sessions were held before starting bromocriptine, on 20 mg/d, and after stopping bromocriptine. The patient's ipsilesional bias increased on bromocriptine, and improved when bromocriptine was stopped. Bromocriptine may worsen neglect if putamenal receptors are damaged. Dopamine agonists may activate the normal hemisphere, increasing an intentional bias. Clinicians using dopaminergic pharmacotherapy should assess patients for this possible adverse effect.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Attention / drug effects
  • Attention / physiology*
  • Brain / drug effects*
  • Brain / pathology
  • Bromocriptine / adverse effects*
  • Bromocriptine / therapeutic use
  • Cerebral Infarction / complications
  • Cerebral Infarction / diagnosis
  • Cerebral Infarction / physiopathology*
  • Cerebral Infarction / rehabilitation*
  • Dopamine Agonists / adverse effects*
  • Dopamine Agonists / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Motor Skills / drug effects
  • Motor Skills / physiology*
  • Movement Disorders / physiopathology*
  • Neuropsychological Tests
  • Videotape Recording

Substances

  • Dopamine Agonists
  • Bromocriptine